Clinical studies

Conducted across four sites in Manchester, ORI-01 enrolled 106 patients, with 66 diagnosed with inflammatory bowel disease (IBD). The study compared rectal mucus calprotectin levels with faecal calprotectin in patients both with and without IBD.

This large-scale, multi-centre trial involved 800 symptomatic patients recruited across four NHS hospitals—Exeter, Shrewsbury, Oxford, and Cornwall. ORI-02 aimed to demonstrate that Oricol could detect colorectal cancer (CRC), confirm the underlying mucus hypothesis, and assess patient acceptability while developing a valuable biobank of samples.

Based at the Royal Devon & Exeter NHS Hospital, this continuing study investigates the performance of Oricol in detecting both colorectal and other gastrointestinal diseases. The cohort includes 50 retrospective CRC samples and 250 prospective cases exploring pancreatic, lung adenocarcinoma, and urothelial cancer controls.

Cutting the worrying and the waiting. The TRIOMIC study, in partnership with the Shrewsbury and Telford Hospital, will reduce the time patients have to wait and worry about a colorectal cancer diagnosis.